| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Revance Therapeutics, Inc.
13D/A
RVNC · 761330109
|
6.2% |
1/30/2025
Event 1/30/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.